- Subject index
With escalating healthcare costs, changes to the regulatory control on pharmaceutical industries and the inevitable adjustments made in policies and investment in healthcare there is enormous interest in the commercial as well as the scientific aspects of today's healthcare industry.
The SAGE Handbook of Healthcare provides an authoritative analysis of the current (and anticipated) developments in the global healthcare industries. Providing a unique perspective that interfaces between the science and business aspects, it combines information on the latest scientific developments with applied, commercial business data from the global marketplace.
The Handbook focuses on the aspects of paramount importance in the healthcare sector: Pharmacoeconomics; Pharmacogenomics; Therapeutics; Diagnostics
Areas covered include: The role of nanotechnology, genomics and cell therapy in medicine; Diagnostics; Biomarkers and technological advances; Case studies in oncology ...
Chapter 1: Medicare Part D: An Outlook
Medicare Part D: An Outlook
The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (more commonly known as the Medicare Modernization Act or MMA) is widely recognized as the most radical reform in the long history of this insurance program. The MMA's most significant achievement is the introduction of Medicare Part D, a wide-ranging new outpatient prescription drug benefit. Yet, the debut of this important new venture was anything but auspicious. The program's launch in January 2006 was beset by problems: a bewildering choice of plans, slow initial enrollment, criticism of the benefit's design (especially the notorious coverage gap), refusal of coverage for some beneficiaries' medicines in the program's first few weeks, and long delays in the reimbursement of pharmacies.